Companies
-
Have travel restrictions impacted Atlas Arteria’s value?
Andreas Lundberg
December 3, 2020
In this week’s video insight Andreas discusses Atlas Arteria’s major asset, the 31 per cent stake in APRR, a 2300 km motorway network in France. Coronavirus travel restrictions have seen Atlas Arteria’s first-half revenues decline 25 per cent. But is the worst over? continue…
by Andreas Lundberg Posted in Companies, Editor's Pick, Stocks We Like, Video Insights.
- save this article
- POSTED IN Companies, Editor's Pick, Stocks We Like, Video Insights
-
Freedom Foods – significant control deficiencies cost $591.5m
David Buckland
December 2, 2020
The meaningless historical accounts signed off by Deloitte Touche Tohmatsu, came to a head on Monday 30 November when Freedom Foods Group Limited (ASX: FNP) released its Annual Report for the year to 30 June 2020. continue…
by David Buckland Posted in Companies.
- save this article
- POSTED IN Companies
-
Why Flight Centre shares are soaring again
Joseph Kim
December 1, 2020
The good news on coronavirus vaccines has boosted the value of travel stocks, like Flight Centre (ASX:FLT), Webjet (ASX:WEB) and Corporate Travel (ASX:CTD). While a return to normal is still a fair way off, many investors clearly don’t seem to mind, and are looking ahead to better times. So, are they being realistic, or is this a case of irrational exuberance? continue…
by Joseph Kim Posted in Companies.
- 2 Comments
- save this article
- POSTED IN Companies
-
The consumer businesses that should thrive in 2021
Roger Montgomery
November 30, 2020
The COVID-19 lockdowns brought massive changes to consumer behaviour this year. Now, the economic re-opening is bringing a new set of changes. These should benefit many of the consumer businesses that suffered during the lockdowns, thus providing some great opportunities for investors. Let’s look at some of the businesses that should thrive in 2021. continue…
by Roger Montgomery Posted in Companies, Consumer discretionary.
- save this article
- POSTED IN Companies, Consumer discretionary
-
Lovisa supercharges their European growth
David Buckland
November 26, 2020
Early this year Lovisa Holdings Limited (ASX:LOV) celebrated its tenth birthday and this coincided with the Company’s share price hitting a pandemic low in March 2020 of $2.45. It has since rallied 4.5-fold to the current $11.20, giving a market capitalisation on 107.5 shares of $1.2 billion. continue…
by David Buckland Posted in Companies, Stocks We Like.
- save this article
- POSTED IN Companies, Stocks We Like
-
WHITEPAPER
INTEREST RATES, THE BEST IT GETS. IT’S TIME TO DEPLOY CASH
Curious about the investment landscape in 2024? It appears that the current market offers a plethora of enticing opportunities for investors, a rarity not experienced since pre-pandemic times. This unique scenario stems from a confluence of factors, including elevated yields and comparatively rational equity valuations.
READ HERE -
Is Qantas returning to normal, or something better?
Tim Kelley
November 23, 2020
Back in May, we wrote about potential investment merit in Qantas, noting that, while airlines do not readily fit into the “exceptional business” category, we could see good reasons why an investor might be attracted to Qantas (ASX:QAN) at the mid-$3 price that prevailed at the time. continue…
by Tim Kelley Posted in Airlines, Companies.
- save this article
- POSTED IN Airlines, Companies
-
Why our confidence in EML has increased
Dominic Rose
November 20, 2020
News of a potentially highly effective COVID-19 vaccine has provided a welcomed boost for so called ‘out and about’ stocks which are viewed as key beneficiaries of an economic re-opening scenario. Over the past few months, the Montgomery Small Companies Fund has been busy seeking ‘vaccine insurance’ to position the portfolio further towards the re-opening trade. continue…
by Dominic Rose Posted in Companies, Stocks We Like.
- 2 Comments
- save this article
- POSTED IN Companies, Stocks We Like
-
Winners and losers from vaccine announcements
Joseph Kim
November 17, 2020
In a year full of big moves and volatile share prices, last Tuesday saw one of the biggest disparities in the share price performance of the so called “growth vs value” stocks. The spark was the announcement from the Pfizer and BioNTech’s vaccine, which led to a significant rotation into the traditional “value” stocks, funded largely by profit taking in many growth stocks. continue…
by Joseph Kim Posted in Companies, Market commentary.
- save this article
- POSTED IN Companies, Market commentary
-
How much further will the WES share price run?
Stuart Jackson
November 16, 2020
Wesfarmers’ (ASX:WES) trading update for the first four months of FY21 showed the robustness of its retailing businesses. Sales growth for its two best-known brands, Bunnings and Officeworks, was particularly strong, as was the performance of its online channel, Catch. continue…
by Stuart Jackson Posted in Companies, Stocks We Like.
- save this article
- POSTED IN Companies, Stocks We Like
-
How big MAQ’s whopper deal could supersize the business
Gary Rollo
November 13, 2020
Macquarie Telecom (ASX:MAQ) is a leading Australian telecom and datacentre provider. Its datacentre business is booming as more and more organisations shift their computing architecture to the Cloud. Now, a major new expansion project promises to propel the business to even greater heights. continue…
by Gary Rollo Posted in Companies, Stocks We Like.
- 2 Comments
- save this article
- POSTED IN Companies, Stocks We Like
